Novartis' Sandoz Foresees Rapid Growth Post Spin-Off in Generics Market Amid Upcoming Patent Expirations
Portfolio Pulse from Vandana Singh
Novartis' generics unit Sandoz expects to add $3 billion in annual sales over the next five years after spinning out of its parent company. The growth will come from biosimilars and complex generics, with a pipeline of 24 products and over 400 core generic products. Novartis anticipates mid-single-digit net sales growth for Sandoz between 2024 and 2028.
June 08, 2023 | 11:57 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Novartis' generics unit Sandoz expects significant growth after spinning out, with $3 billion in additional annual sales over the next five years. Novartis anticipates mid-single-digit net sales growth for Sandoz between 2024 and 2028.
Sandoz's expected growth in annual sales and the anticipated mid-single-digit net sales growth for the unit between 2024 and 2028 will likely have a positive impact on Novartis' stock price in the short term. The growth in the generics market, driven by upcoming patent expirations, further supports this positive outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100